Tirzepatide: Safety Profile & Research Summary
13 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: April 2026
Key Clinical Studies
| Study | Design | Key Outcome |
|---|---|---|
| Jeppesen et al. (2012) — STEPS | Phase III, RCT, n=86 adults with SBS-IF | ≥20% PS reduction in 63% teduglutide vs 30% placebo (p=0.002) |
| Schwartz et al. (2016) — STEPS-2 | OLE, n=88, up to 2 years | 66% PS reduction at 2 years; 13% achieved enteral autonomy |
| Kocoshis et al. (2020) — Pediatric | Phase III, n=59, ages 1–17 years | 54% responders vs 23% SOC; safety consistent with adults |
| Drucker et al. (1996) | Preclinical (foundational) | Established GLP-2 as intestinotrophic factor; mucosal growth in mice |
| Jeppesen et al. (2005) — Phase II | Phase II, n=16, SBS adults | Increased intestinal wet weight absorption; proof of concept |
Research Dosing Reference (Approved Label Data)
| Parameter | Value |
|---|---|
| Approved dose (adults) | 0.05 mg/kg SC once daily |
| Approved dose (pediatric ≥1 yr) | 0.05 mg/kg SC once daily |
| Administration route | Subcutaneous injection (alternating quadrants of abdomen, thighs, upper arms) |
| Renal impairment | 50% dose reduction for moderate-severe renal impairment and ESRD |
| Response assessment | Evaluate PS reduction at 6 months; discontinue if no meaningful response |
Safety Profile (Pooled Clinical Data)
| Observation | Detail |
|---|---|
| Most common adverse effects | Abdominal pain (30%), injection site reactions (22%), nausea (18%), headache (16%), abdominal distension (14%) |
| GI stoma complications | Reported in patients with stomas; monitor stoma output and size |
| Fluid overload risk | As absorption improves, parenteral support must be reduced to avoid fluid overload |
| Colorectal polyps | Colonoscopy required within 6 months before starting and at least every 5 years during treatment (FDA label requirement) |
| Gallbladder/biliary disease | Monitor for cholecystitis and cholelithiasis; GLP-2 affects gallbladder motility |
| Pancreatic/hepatobiliary | Monitor for pancreatitis; rare reports of pancreatic/biliary disease |
In Vitro / Preclinical Disclaimer: The findings described above include data from in vitro laboratory studies, preclinical animal research, and human clinical trials. Research-grade teduglutide sold here is not equivalent to the FDA-approved pharmaceutical product (Gattex®/Revestive®). This information is provided solely for scientific and educational reference regarding published research into this compound.
Educational Use Only: All information on this page is intended for educational and research reference purposes only. Research-grade teduglutide is sold strictly for laboratory research use in accordance with applicable law. This content does not constitute medical advice.
References
- Drucker DJ, et al. (1996). Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol, 15(7):673–677.
- Drucker DJ, Yusta B. (2014). Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol, 76:561–583.
- FDA. (2012). NDA 203441 Approval Letter — Gattex (teduglutide) for injection. U.S. Food and Drug Administration.
- Drucker DJ, et al. (1996). Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA, 93(15):7911–7916.
- Jeppesen PB, et al. (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology, 143(6):1473–1481.
- Leen JLS, et al. (2011). Mechanism of action of glucagon-like peptide 2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology, 152(2):436–446.
- Jeppesen PB, et al. (2005). Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 54(9):1224–1231.
- Gattex (teduglutide) Prescribing Information. (2019). Takeda Pharmaceuticals USA, Inc.
- Schwartz LK, et al. (2016). Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol, 7(2):e142.
- Jeppesen PB, et al. (2018). Factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure. Gastroenterology, 154(4):874–885.
- Kocoshis SA, et al. (2020). Safety and efficacy of teduglutide in pediatric patients with short bowel syndrome—intestinal failure. J Pediatr Gastroenterol Nutr, 70(4):521–528.
- Hukkinen M, et al. (2019). Parenteral nutrition-associated cholestasis and its association with teduglutide treatment in neonatal short bowel syndrome. J Pediatr Surg, 54(11):2281–2287.
- Drucker DJ, et al. (1999). Glucagon-like peptide 2 reduces intestinal permeability. Am J Physiol, 276(6):G1420–G1426.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.